NUVB
Nuvation Bio Inc.
NEW YORK STOCK EXCHANGE, INC.· Pharmaceuticals· US· IPO 2020-07-01
$4.69
+0.10 (+2.18%)
last quote
Want the full multi-source brief on NUVB?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$4.69
High
$4.79
Low
$4.61
Previous close
$4.59
Fundamentals
Market cap
$1.62B
P/E (TTM)
—
P/S (TTM)
9.51x
P/B
10.08x
Gross margin
88.18%
Operating margin
-86.58%
Net margin
-88.19%
Rev growth (YoY)
1083.56%
EPS growth (YoY)
—
ROE
-49.73%
52W high
$9.75
52W low
$3.92
Beta
1.77x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-04todayafter market
Q3 2026EPS est $-0.13Rev est $34.9M
Recent SEC filings
CIK 1811063filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 22h
Top 3 Penny Stocks To Watch In November 2026
Australia’s central bank just pushed interest rates to an 18 year high of 4.85%, which puts serious pressure on heavily indebted firms and speculative stories. That kind of backdrop rewards investors who focus on smaller, low priced stocks with cleaner finances instead of fragile balance sheets. This article spotlights three financially fit penny stocks from the screener that aim to combine early
Yahoo · 1d
Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of +5.13% and +2.56%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · 1d
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional updated results from the Phase 2 J201 study and three posters on ongoing studies of safusidenib, its selective investigational inhibitor of mutant IDH1, will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting taking plac
Benzinga · 2d
Nuvation Bio To Present Updated Data From Its Phase 2 J201 Trial, Three Posters On Ongoing Studies Of Safusidenib At Society For Neuro-Oncology Annual Meeting
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional updated results from the Phase 2 J201 study and three
Yahoo · 6d
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the pivotal Phase 3 SIGMA (G203; NCT05303519) study of investigational safusidenib will expand to include study sites in the United Kingdom, France, Sweden, Germany, Italy and Spain. These additional countries extend SIGMA's global footprint beyond
Benzinga · 6d
Nuvation Bio Plans To Add Sites In Six European Countries For Its Pivotal Phase 3 SIGMA Study Of Safusidenib
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the pivotal Phase 3 SIGMA (G203; NCT05303519) study of
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial